The UK and US have agreed to a important bilateral deal that will guarantee no duties on British drug shipments being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase spending on drugs through the NHS. This pledge secures that tariffs on these crucial products will be held at zero for a timeframe of 36 months.
This development is in response to recent statements to dramatically increase duties on branded drug imports, with potential rates discussed reaching one hundred percent.
"This agreement between the Britain reinforces the worldwide climate for innovative medicines and establishes much-needed equity to American-British pharmaceutical trade," a statement noted.
Economic Impact
Medicines constitute one of the UK's largest export categories to the United States, which is clearly the largest buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of last September, the UK shipped drugs totaling £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that period.
"This guarantee safeguards jobs, boosts capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," a minister remarked.
Key UK Commitments
The deal involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, rebates exceeded twenty percent.
Recent Tensions
The deal follows a protracted tension between the sector and the UK government over drug pricing and NHS adoption.
This friction were intensified by claims that US consumers were paying a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while substantial investments have been directed toward American operations.
One official stated that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a percentage of its resources over the last ten years.
